(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 October 2018 (18.10.2018)

WIPO | PCT

(10) International Publication Number
WO 2018/190719 A3

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61K 39/00* (2006.01)

(21) International Application Number:
PCT/NL2018/050234

(22) International Filing Date:
13 April 2018 (13.04.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

2018708	13 April 2017 (13.04.2017)	NL
2019166	03 July 2017 (03.07.2017)	NL

(71) Applicant: **ADURO BIOTECH HOLDINGS, EUROPE B.V.** [NL/NL]; Kloosterstraat 9 RX1101, 5349 AB Oss (NL).

(72) Inventors: **VAN EENENNAAM, Hans**; c/o Kloosterstraat 9 RX1101, 5349 AB Oss (NL). **VAN ELSAS, Andrea**; c/o Kloosterstraat 9 RX1101, 5349 AB Oss (NL). **VOETS, Erik**; c/o Kloosterstraat 9 RX1101, 5349 AB Oss (NL). **VINK, Paul**; c/o Kloosterstraat 9 RX1101, 5349 AB Oss (NL). **HULSIK, David Lutje**; c/o Kloosterstraat 9 RX1101, 5349 AB Oss (NL).

(74) Agent: **HOFFMANN EITLE**; Patent- und Rechtsanwalte PartmbB, Arabellastr. 30, 81925 München (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
31 October 2019 (31.10.2019)

WO 2018/190719 A3

(54) Title: ANTI-SIRP ALPHA ANTIBODIES

(57) Abstract: The present invention relates to anti-SIRPα antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.

INTERNATIONAL SEARCH REPORT

International application No
PCT/NL2018/050234

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07K16/28
ADD. A61K39/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2013/056352 A1 (UNIV HEALTH NETWORK [CA]; HOSPITAL FOR SICK CHILDREN [CA]; WANG JEAN C) 25 April 2013 (2013-04-25)	1-63
Y	p 20, l15-17; p 21, l 13-16; p 2, l 30 - p 3, l 2; p 13, l 18 ff; p 27, l 15 ff; paragraph [examples]; claims 1-26; figure 5	1-63

X	TADAHIKO YANAGITA ET AL: "Anti-SIRP[alpha] antibodies as a potential new tool for cancer immunotherapy", JCI INSIGHT, vol. 2, no. 1, 12 January 2017 (2017-01-12), XP055421877, ISSN: 2379-3708, DOI: 10.1172/jci.insight.89140	1-63
Y	the whole document	1-63

	-/--	

[X] Further documents are listed in the continuation of Box C.

[X] See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
6 September 2019	23/09/2019

Name and mailing address of the ISA/	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Lechner, Oskar

2

Form PCT/ISA/210 (second sheet) (April 2005)

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 00/66159 A1 (FACULTEIT DER GENEESKUNDE VAN [NL]; DEN BERG TIMO KARS VAN [NL]; DIJKS) 9 November 2000 (2000-11-09) paragraph [discussion]; claims 1-14; figures 1-3	1-63
Y	K. WEISKOPF ET AL: "Engineered SIRP Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies", SCIENCE, vol. 341, no. 6141, 30 May 2013 (2013-05-30), pages 88-91, XP055223925, ISSN: 0036-8075, DOI: 10.1126/science.1238856 abstract	1-63
Y	WO 2015/138600 A2 (UNIV LELAND STANFORD JUNIOR [US]) 17 September 2015 (2015-09-17) par 149-151; claims 1-36	1-63
X,P	WO 2017/178653 A2 (OSE IMMUNOTHERAPEUTICS [FR]) 19 October 2017 (2017-10-19)	1-63
Y,P	claims 1-25	1-63
A	A. P. A. THEOCHARIDES ET AL: "Disruption of SIRP signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts", BLOOD, vol. 119, no. 18, 3 September 2012 (2012-09-03), pages 4333-1899, XP055126663, ISSN: 0006-4971, DOI: 10.1182/blood-2011-11-391367 the whole document	1-63
A	HANKE L. MATLUNG ET AL: "The CD47-SIRP[alpha] signaling axis as an innate immune checkpoint in cancer", IMMUNOLOGICAL REVIEWS., vol. 276, no. 1, 1 March 2017 (2017-03-01) , pages 145-164, XP055429046, US ISSN: 0105-2896, DOI: 10.1111/imr.12527	1-63
T	WO 2018/190719 A2 (ADURO BIOTECH HOLDINGS EUROPE B V [NL]) 18 October 2018 (2018-10-18)	1-63
T	WO 2018/210793 A2 (SYNTHON BIOPHARMACEUTICALS BV [NL]) 22 November 2018 (2018-11-22)	1-63

2 -/--

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	RUDIKOFF S ET AL: "Single amino acid substitution altering antigen-binding specificity", NATIONAL ACADEMY OF SCIENCES, US, vol. 79, 1 March 1982 (1982-03-01), pages 1979-1983, XP007901436, ISSN: 0027-8424, DOI: 10.1073/PNAS.79.6.1979	1-63
T	YEE WAH WONG ET AL: "Structural Requirements for a Specificity Switch and for Maintenance of Affinity Using Mutational Analysis of a Phage-Displayed Anti-Arsonate Antibody of Fab Heavy Chain First Complementarity-Determining Region", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, INC, US, vol. 160, 1 January 1998 (1998-01-01), pages 5990-5997, XP007916801, ISSN: 0022-1767	1-63
T	JEFFEREY R JACKSON: "In Vitro Antibody Maturation Improvement of a High Affinity, Neutralizing Antibody Against IL-1 beta", THE JOURNAL OF IMMUNOLOGY, vol. 154, 1 January 1995 (1995-01-01), pages 3310-3319, XP055033979,	1-63

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/NL2018/050234

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2013056352 A1	25-04-2013	US 2014242095 A1	28-08-2014
		WO 2013056352 A1	25-04-2013
WO 0066159 A1	09-11-2000	AU 779221 B2	13-01-2005
		CA 2371421 A1	09-11-2000
		EP 1048299 A1	02-11-2000
		EP 1173202 A1	23-01-2002
		JP 2002543153 A	17-12-2002
		US 2002114807 A1	22-08-2002
		WO 0066159 A1	09-11-2000
WO 2015138600 A2	17-09-2015	AU 2015229448 A1	01-09-2016
		CA 2939293 A1	17-09-2015
		CN 106456749 A	22-02-2017
		EP 3116544 A2	18-01-2017
		JP 2017510251 A	13-04-2017
		SG 11201607143U A	29-09-2016
		US 2017073414 A1	16-03-2017
		US 2018319883 A1	08-11-2018
		WO 2015138600 A2	17-09-2015
WO 2017178653 A2	19-10-2017	AU 2017248626 A1	11-10-2018
		BR 112018070823 A2	05-02-2019
		CA 3020373 A1	19-10-2017
		CN 109071664 A	21-12-2018
		CO 2018010855 A2	13-11-2018
		EA 201891882 A1	31-07-2019
		EP 3443010 A2	20-02-2019
		KR 20180134397 A	18-12-2018
		PE 19212018 A1	11-12-2018
		SG 11201808465U A	30-10-2018
		WO 2017178653 A2	19-10-2017
WO 2018190719 A2	18-10-2018	TW 201841943 A	01-12-2018
		US 2018312587 A1	01-11-2018
		WO 2018190719 A2	18-10-2018
WO 2018210793 A2	22-11-2018	AR 111630 A1	31-07-2019
		TW 201906860 A	16-02-2019
		WO 2018210793 A2	22-11-2018
		WO 2018210795 A1	22-11-2018